Lion's mane (Hericium erinaceus) has one of the more devoted followings in the supplement world, and one of the thinner human evidence bases relative to that popularity. "Is it worth it" is a fair question, and the honest answer is a genuine "it depends what you mean by worth it" rather than a clean yes or no. Here is what the actual human trials found, who they studied, and what that does and does not tell you.

This article is educational and is not medical advice. Supplements are not intended to diagnose, treat, cure, or prevent any disease. Talk to a qualified clinician before starting anything new.

What the human trials actually looked at

We grade lion's mane Emerging on this site: some small human trials and considerable preclinical work, but a human evidence base that is still limited and preliminary. That grade is not a dismissal; it is an accurate description of where the research stands. Reviewed again in September 2026, when we went looking for every human trial rather than the ones usually quoted. Three small trials make up most of the evidence people point to, and a second group of trials, the ones that did enrol healthy adults, mostly found nothing.

  • Mori et al. (2009): a randomized, double-blind, placebo-controlled trial in 30 Japanese adults aged 50–80 with diagnosed mild cognitive impairment. Participants took 3 g/day of Yamabushitake (lion's mane) extract for 16 weeks and showed significantly higher scores on a cognitive function scale versus placebo at weeks 8, 12, and 16, but the gains declined within four weeks of stopping.
  • Nagano et al. (2010): a randomized trial in 30 women, using lion's mane cookies versus placebo cookies over 4 weeks, that found lower depression and anxiety scores in the lion's mane group.
  • Vigna et al. (2019): an open-label pilot study with a control group in 77 adults with overweight or obesity and an existing mood or sleep complaint, using 1,500 mg/day of a mycelium-and-fruiting-body extract over 8 weeks, which found reduced anxiety alongside increased circulating pro-BDNF (a neurotrophic-signaling marker).

Read those three studies carefully and a pattern emerges: small sample sizes (30 to 77 people), specific and non-generalizable populations (older adults with diagnosed cognitive impairment, women with mood complaints, adults with overweight or obesity and existing sleep or mood issues), and short durations (4 to 16 weeks). None of them enrolled healthy, cognitively unimpaired young or middle-aged adults, the population most people buying lion's mane for "focus" actually are.

The trials that did study healthy adults

That last point used to be the end of the story. It is not any more. Healthy adults have now been studied several times, and the results are mostly null. That is more informative than an absence of trials, and it is the main thing that changed when we re-reviewed this ingredient in September 2026.

  • Docherty et al. (2023): 41 healthy adults aged 18–45. A single dose produced faster Stroop performance at 60 minutes, but the 28-day results were mostly null, and delayed word recall was worse than placebo.
  • Surendran et al. (2025): 18 healthy adults aged 18–35, a single 3 g dose of a 10:1 fruiting-body extract. No effect on the composite measures of global cognition or mood; one fine-motor test improved at 90 minutes.
  • Grozier et al. (2022): 24 college-age adults took 10 g/day in muffins for four weeks. Nothing changed, on any cognitive or metabolic measure.
  • La Monica et al. (2023): a single 1 g dose of a Nordic-grown fruiting-body extract improved reaction-time measures over two hours, in a trial run by a contract research organisation.
  • Černelič Bizjak et al. (2024): 33 adults aged 55–75 took an erinacine-A-standardized extract for 8 weeks. Two non-verbal speed tests improved, but only in a statistical model adjusting for baseline score, age, sex and a biomarker, and cognition was a secondary outcome of a trial registered to study the gut microbiome.
  • A 2026 preprint in 150 adults aged 40–75 reported an improvement on one visual attention and working-memory task at 2 g/day for 8 weeks, but not on the memory tasks or the composite score. It was funded by an ingredient supplier that employs two of its lead authors, more than a quarter of those randomized were not analysed, and it had not passed peer review when we checked in September 2026.

What this does and does not support

  • Supports: a real, if early, signal that lion's mane may help specific outcomes (cognitive scores in diagnosed MCI, mood and anxiety measures) in specific, studied populations, over weeks of daily use.
  • Does not support: a reliable same-day "focus" effect. Three trials did measure acute outcomes, and they disagree. A single dose sped up Stroop performance at 60 minutes in one (Docherty 2023) and reaction-time measures over two hours in another (La Monica 2023), while a third found nothing on its global cognition composite (Surendran 2025). Different extracts, different tasks, no replication between them.
  • Does not support: meaningful cognitive enhancement in healthy, non-impaired adults. This population has now been studied several times, and the trials mostly found no effect.
  • Does not support: any specific dose as definitively "correct". The trials span 1 g to 10 g/day across powders, cookies, fruiting-body extracts, mycelium blends and an erinacine-A-standardized extract, and none of those preparations has been compared head-to-head with another.
Small, promising early trials in narrow populations are a legitimate reason for interest, but they are not the same evidentiary weight as the multi-trial, healthy-adult evidence behind an ingredient like L-theanine. Calibrate expectations to the actual trial population, not the marketing pitch.

Building a cleaner stack? The Clean Focus Stack Guide is free when you join the Signal State waitlist. Get the guide

The product-quality problem is real and separate from the evidence question

Even if you accept the early human signal at face value, lion's mane has an unusually large label-literacy gap between products. "Fruiting body" and "mycelium" are not interchangeable, and mycelium-on-grain products can be diluted with substrate starch that inflates weight without adding active compound. Beta-glucan content, one of the more meaningful potency markers, is inconsistently disclosed. Two bottles both labeled "Lion's Mane 500 mg" can deliver meaningfully different amounts of active material, and the label alone often will not tell you which one you are holding.

  • Prefer fruiting-body extracts with a stated beta-glucan percentage over undefined mycelium-on-grain products.
  • Be skeptical of a label that lists only "total polysaccharides" without specifying beta-glucan content.
  • Treat any specific studied dose as tied to a specific extract type: 3 g/day of one preparation is not obviously equivalent to 3 g/day of another.

Cautions worth knowing

  • It is a mushroom. Anyone with a known mushroom allergy should avoid it, and rash or breathing symptoms warrant stopping and seeking care.
  • Long-term daily use of concentrated extracts is essentially uncharacterized beyond the 16-week window of the longest trial.
  • Pregnancy, breastfeeding, and use in children are unstudied. The conservative position is to avoid.
  • Interaction data is limited; theoretical considerations around blood clotting and blood sugar mean people on anticoagulants or diabetes medication should check with a pharmacist first.

So, is it worth it?

"Worth it" depends entirely on what you are measuring against. As a proven, well-established cognitive enhancer for a healthy adult, the evidence does not support that framing. The trials in that population have mostly come back null, and the older positive trials targeted specific conditions (diagnosed mild cognitive impairment, existing mood complaints) in distinct groups. As a low-risk, early-stage ingredient with a genuinely interesting, if thin, human signal and a long culinary safety history, it is a defensible thing to be curious about, provided you go in with calibrated expectations, a reasonable extract with disclosed beta-glucan content, and patience for a multi-week trial rather than a same-day effect.

References

This article draws on the primary human research below; see the linked studies for full methods and doses.

  • Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial." Phytotherapy Research, 2009;23(3):367–372. PMID: 18844328.
  • Nagano M, Shimizu K, Kondo R, et al. "Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake." Biomedical Research, 2010;31(4):231–237. PMID: 20834180.
  • Vigna L, Morelli F, Agnelli GM, et al. "Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?" Evidence-Based Complementary and Alternative Medicine, 2019;2019:7861297. PMID: 31118969.
  • Docherty S, Doughty FL, Smith EF. "The Acute and Chronic Effects of Lion's Mane Mushroom Supplementation on Cognitive Function, Stress and Mood in Young Adults: A Double-Blind, Parallel Groups, Pilot Study." Nutrients, 2023;15(22). PMID: 38004235.
  • Surendran G, Saye J, Binti Mohd Jalil S, et al. "Acute effects of a standardised extract of Hericium erinaceus (Lion’s Mane mushroom) on cognition and mood in healthy younger adults." Frontiers in Nutrition, 2025;12:1405796. PMID: 40276537.
  • Grozier CD, Alves VA, Killen LG, et al. "Four Weeks of Hericium erinaceus Supplementation Does Not Impact Markers of Metabolic Flexibility or Cognition." International Journal of Exercise Science, 2022;15(2):1366–1380. PMID: 36582308.
  • La Monica MB, Raub B, Ziegenfuss EJ, et al. "Acute Effects of Naturally Occurring Guayusa Tea and Nordic Lion’s Mane Extracts on Cognitive Performance." Nutrients, 2023;15(24):5018. PMID: 38140277.
  • Černelič Bizjak M, Jenko Pražnikar Z, Kenig S, et al. "Effect of erinacine A-enriched Hericium erinaceus supplementation on cognition: a randomized, double-blind, placebo-controlled pilot study." Journal of Functional Foods, 2024;115:106120.